Contribution ID: 327

Type: Oral talk (15 min + 5 min questions)

NASOLACRIMAL DUCTS PHARMACOSAFETY OF 131-IODINE

Friday, 15 July 2022 16:00 (20 minutes)

Secondary obliteration of the lacrimal duct obstruction (SALDO) is one of radioiodine therapy complications in differentiated thyroid cancer observed in 9% of cases [1]. Development of methods for the prevention of SALDO one of the urgent tasks facing radiology and ophthalmology [2]. We analyzed the frequency of 131-iodine uptake nasolacrimal ducts in 203 patients on 72 h. after 131-iodine administration. Patients were divided in two groups according type of preparation to the radioiodine therapy: 103 used classic levothyroxine withdrawal for 3 weeks, 100 used recombinant human thyroid stimulating hormone to increase TSH level. Image segmentation method was developed for static 131-iodine scintigraphy of head and neck. Additionally, we made an attempt to highlight several groups of risk to develop SALDO in patients undergoing 131-iodine therapy.

The speaker is a student or young scientist

Yes

Section

1. Nuclear technology and methods in medicine, radioecology

Primary authors: TRUKHIN, Alexey (Endocrinology Research Centre); Mr YARTSEW, Vasiliy (FSBI «RIED»); Mr UDAKOV, Danila (Endocrinology Research Centre)

Presenter: TRUKHIN, Alexey (Endocrinology Research Centre)

Session Classification: Nuclear technology and methods in medicine, radioecology.